Hetero — Indian Generic Medicine Manufacturer
Hetero
Hetero is an Indian pharmaceutical group founded in 1993 by Dr B. Parthasaradhi Reddy and headquartered in Hyderabad, Telangana. It is privately held and not listed on a stock exchange.
Hetero makes active pharmaceutical ingredients, generics, branded generics and biosimilars. It is described as the world's largest producer of antiretroviral drugs for HIV. It also has a broad portfolio of hepatitis C, oncology and haematology medicines, and has made biosimilars since 2015, including rituximab, with bevacizumab following in 2016.
Hetero is a long-standing Gilead licensee: in 2014 it received the right to make sofosbuvir for hepatitis C, and in 2020 to produce generic remdesivir for 127 countries. Its Covifor was the first remdesivir approved in India.
Manufacturing is concentrated in India, including an API complex in a special economic zone in Visakhapatnam. Abroad the group operates through subsidiaries such as Camber Pharmaceuticals in the US and Amarox in Europe and the Gulf states.
Unifarm carries Hetero medicines: Piclib (palbociclib), Nitib (ibrutinib), Acalnib (acalabrutinib), Crikzo (crizotinib), Maball (rituximab), Cizumab (bevacizumab), Azashine (azacitidine), Velasof (sofosbuvir and velpatasvir), Taffic (bictegravir, emtricitabine and tenofovir alafenamide) and more — see the full list below.